<DOC>
	<DOC>NCT01304511</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to identify problems and questions regarding the safety and efficacy of Orgalutran (Ganirelix)® when used for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).</brief_summary>
	<brief_title>Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®</brief_title>
	<detailed_description />
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Must be undergoing COH for ART Hypersensitivity to the active substance or to any of the excipients Hypersensitivity to gonadotropinreleasing hormone (GnRH) or any other GnRH analogue Moderate or severe impairment of renal or hepatic function Pregnancy or lactation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>